Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

Trial Details

NCT ID
NCT04115306
Phase
PHASE1 / PHASE2
Sponsor
Phoenix Molecular Designs
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • PMD-026
  • fulvestrant
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Los Angeles, California, United States|34.05223,-118.24368
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • RSK2 positive from available archival or fresh tumor tissue (FFPE).
  • Histologically or cytologically diagnosed HR+, HER2-
  • ESR1 wild type
  • Diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amendable to resection or radiation with curative in…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →